Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425503 · ClinicalTrials.gov registry record · Phase 2
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
A Phase 2 study of Prostate Neoplasms, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00425503 is a Phase 2 study of Prostate Neoplasms that has completed, run by Baylor College of Medicine. The registered enrollment target is 40 participants, below the 141-participant average among 4 other Prostate Neoplasms trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00425503, a Phase 2 study of Prostate Neoplasms, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed. Surgery will be delayed if there is any bleeding abnormality (bleeding time greater than 10 minutes) and until platelet count is more than or equal to 100,000 and coagulation profile (PT, PTT) is normal. If at the time of surgery a patient is found to have positive lymph nodes, prostatectomy will be abandoned, the prostate will be biopsied, and the patient will be offered other treatment modalities (hormones, radiation therapy).
Conditions Studied
Interventions
- DRUG PS-341 (bortezomib)
Study Locations (1)
Texas
- Scott Department of Urology, Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425503
The ClinicalTrials.gov registry entry for NCT00425503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 4 other Prostate Neoplasms trials with a reported enrollment target (72% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PS-341 (bortezomib) is the first listed.
NCT00425503 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00425503 about?
NCT00425503 is a clinical study titled "PS-341 Followed by Removal of Prostate for Those With Prostate Cancer". Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will...
What is the current status of trial NCT00425503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-12. Estimated completion is 2013-12.
What conditions does trial NCT00425503 study?
This clinical trial studies the following conditions: Prostate Neoplasms.
What interventions are being tested in trial NCT00425503?
The interventions under investigation include: PS-341 (bortezomib) (DRUG).
Who is sponsoring clinical trial NCT00425503?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425503 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
COMPLETED · Phase 2
-
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
RECRUITING · Phase 1
-
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.